Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 10, Number 6—June 2004


SARS and Common Viral Infections

Janice K. Louie*†1Comments to Author , Jill K. Hacker*1, Jennifer Mark*, Shilpa S. Gavali*, Shigeo Yagi†, Alex Espinosa†, David P. Schnurr†, Cynthia K. Cossen†, Erin R. Isaacson†, Carol A. Glaser†, Marc Fischer‡, Arthur L. Reingold†, Duc J. Vugia*†, and for the Unexplained DeathsCritical Illnesses Working Group
Author affiliations: *California Emerging Infections Program, Berkeley, California, USA; †California Department of Health Services, Berkeley, California, USA; ‡Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Table 1

Respiratory testing algorithma

Respiratory specimens Serologic testingb
Viral culture Acute-phase serum specimens: IgM
  Polymerase chain reaction Chlamydia spp.
  Influenza A Mycoplasma pneumoniae
  Influenza B Paired serum specimens: IgG
  Respiratory syncytial virus Chlamydia spp.
  Parainfluenza virus types 1–4 M. pneumoniae
  Human metapneumovirus Influenza A and B
  Coronavirus OC43 and 229E Respiratory syncytial virus
  Adenovirus Parainfluenza virus types 2–4
  Picornavirus Adenovirus

aIg, immunoglobulin; SARS-CoV, severe acute respiratory syndrome–associated coronavirus.
bAll serologic assays were in-house enzyme immunoassays (15), except for the Meridian IgM assay for M. pneumoniae (Meridian Bioscience, Inc., Cincinnati, OH) and enzyme-linked immunosorbent assay of the Centers for Disease Control and Prevention for SARS-CoV

Main Article

1Both authors contributed equally to this work.